For inoperable small hepatocellular carcinoma (HCC), stereotactic body radiotherapy (SBRT) is an effective and safe local treatment. Despite satisfactory local control rate, the incidence of recurrence out the field remains substantial, with 2-year PFS of 31.9% to 60.9%. Therefore, a more effective treatment mode is urgently needed. Immune checkpoint inhibitors targeting PD-1/PD-L1 have shown substantial clinical benefits in advanced HCC as well as resected high-risk HCC. Recently, the combination of immunotherapy with SBRT has shown promising activity in HCC, but its utility in small HCC is unclear. The aim of this study was to investigate the efficacy and safety of SBRT followed by sintilimab (an anti-PD-1 antibody) in patients with recurrent or residual small HCC.

开始日期2024-04-05

申办/合作机构

中山大学

[+1]

ChiCTR2400082386 / Recruiting临床2期IIT

Transarterial chemoembolization (TACE) and Stereotactic body radiation therapy (SBRT) Combined with TKIs and Sintilimab for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Single-Arm, Prospective, Phase II Clinical Study

开始日期2024-04-01

申办/合作机构-

NCT06341595 / Recruiting临床2期IIT

Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for Advanced Gastric Cancer Patients With Para-aortic Lymph Node Metastasis: a Single-arm, Phase II, Exploratory Study.

This trial is a prospective, single arm, single center, phase II clinical study aimed at subjects with advanced gastric cancer and para aortic lymph node metastasis, exploring the feasibility and safety of Sintilimab Injection combined with synchronous chemo-radiotherapy as neoadjuvant therapy.
Patients will receive sintilimab Injection (200mg iv q3w d1) combined with concurrent radiotherapy and chemotherapy. The chemotherapy regimen will use oxaliplatin 130mg/m2+S-1 40mg/m2 bid d1-14. Radiotherapy is performed using intraperitoneal radiation therapy, once a day, five times a week, at a dose of 1.8-2 Gy/f, for a total of 45-50.4 Gy (60-66 Gy for lymph node lesions). Radiation therapy starts from the second cycle of Sintilimab Injection combined with chemotherapy. The subjects underwent imaging evaluation after completing 4 cycles of combination chemotherapy and radiation therapy with Sintilimab Injection. Evaluated as a surgical subject (surgical conditions: imaging evaluation of enlarged lymph nodes adjacent to the abdominal aorta with PR or no significant activity), radical surgery will be performed within 4 weeks after the last study drug treatment. After surgery, the researcher will determine the necessity of adjuvant treatment and develop an adjuvant treatment plan based on the subject's condition. Subjects evaluated as inoperable will have their best follow-up treatment plan determined by the researcher.

开始日期2024-04-01

申办/合作机构

南京医科大学第三附属医院

100 项与信迪利单抗相关的临床结果

登录后查看更多信息

100 项与信迪利单抗相关的转化医学

登录后查看更多信息

100 项与信迪利单抗相关的专利（医药）

登录后查看更多信息

2,193

项与信迪利单抗相关的文献（医药）

2024-12-31·OncoImmunology

A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies

Article

作者: Lin, Chia-Chi ; Kyi, Chrisann ; Chiu, Joanne ; Askoxylakis, Vasileios ; Carvajal, Richard D ; Spratlin, Jennifer ; Chowdhury, Niladri Roy ; Garralda, Elena ; Gusenleitner, Daniel ; Maur, Michela ; Esaki, Taito ; Siu, Lillian L ; Sarantopoulos, John ; Rolland, Fréderic ; Cassier, Philippe A ; Zhang, Tian ; Soo, Ross A ; Schöffski, Patrick ; Ma, Brigette ; Martin, Miguel ; Deschler-Baier, Barbara ; Weickhardt, Andrew ; De Braud, Filippo ; Hui, Rina ; Akerley, Wallace ; Rispoli, Lawrence ; Hong, David S ; Samant, Tanay S ; Tan, Daniel Sw ; Kwak, Eunice L

Ieramilimab, a humanized anti-LAG-3 monoclonal antibody, was well tolerated in combination with the anti-PD-1 antibody spartalizumab in a phase 1 study. This phase 2 study aimed to further investigate the efficacy and safety of combination treatment in patients with selected advanced (locally advanced or metastatic) solid malignancies. Eligible patients with non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), mesothelioma, and triple-negative breast cancer (TNBC) were grouped depending on prior anti-PD-1/L1 therapy (anti-PD-1/L1 naive or anti-PD-1/L1 pretreated). Patients received ieramilimab (400 mg) followed by spartalizumab (300 mg) every 3 weeks. The primary endpoint was objective response rate (ORR), along with safety, pharmacokinetics, and biomarker assessments. Of 235 patients, 142 were naive to anti-PD-1/L1 and 93 were pretreated with anti-PD-1/L1 antibodies. Durable responses (>24 months) were seen across all indications for patients naive to anti-PD-1/L1 and in melanoma and RCC patients pretreated with anti-PD1/L1. The most frequent study drug-related AEs were pruritus (15.5%), fatigue (10.6%), and rash (10.6%) in patients naive to anti-PD-1/L1 and fatigue (18.3%), rash (14.0%), and nausea (10.8%) in anti-PD-1/L1 pretreated patients. Biomarker assessment indicated higher expression of T-cell-inflamed gene signature at baseline among responding patients. Response to treatment was durable (>24 months) in some patients across all enrolled indications, and safety findings were in accordance with previous and current studies exploring LAG-3/PD-1 blockade.

2024-12-31·OncoImmunology

LFA-1 regulated by IL-2/STAT5 pathway boosts antitumor function of intratumoral CD8 ⁺ T cells for improving anti-PD-1 antibody therapy

Article

作者: Shen, Chunyi ; Jing, Wei ; Zhang, Yi ; Shan, Jiqi ; Ping, Yu ; Liu, Yaqing ; Liu, Fengsen ; Han, Dong ; Li, Congcong

Anti-PD-1 antibody therapy has achieved success in tumor treatment; however, the duration of its clinical benefits are typically short. The functional state of intratumoral CD8⁺ T cells substantially affects the efficacy of anti-PD-1 antibody therapy. Understanding how intratumoral CD8⁺ T cells change will contribute to the improvement in anti-PD-1 antibody therapy. In this study, we found that tumor growth was not arrested after the late administration of anti-PD-1 antibody and that the antitumor function of CD8⁺ T cells decreased with tumor progression. The results of the RNA sequencing of CD8⁺ T cells infiltrating the tumor site on days 7 and 14 showed that the cell adhesion molecule Lymphocyte Function-associated Antigen-1 (LFA-1) participates in regulating the antitumor function of CD8⁺ T cells and that decreased LFA-1 expression in intratumoral CD8⁺ T cells is associated with tumor progression. By analyzing the Gene Expression Omnibus (GEO) database and our results, we found that the antitumor function of intratumoral CD8⁺ T cells with high LFA-1 expression was stronger. The formation of immune synapses is impaired in Itgal-si CD8⁺ T cells, resulting in decreased anti-tumor function. LFA-1 expression in intratumoral CD8⁺ T cells is regulated by the IL-2/STAT5 pathway. The combination of IL-2 and anti-PD-1 antibody effectively enhanced LFA-1 expression and the antitumor function of intratumoral CD8⁺ T cells. The adoptive transfer of OT-1 T cells overexpressing LFA-1, STAT5A, or STAT5B resulted in higher antitumor function, deferred tumor growth, and prolonged survival. These findings indicate that LFA-1-mediated immune synapse acts as a regulator of the antitumor function of intratumoral CD8⁺ T cells, which can be applied to improve anti-PD-1 antibody therapy.

2024-04-01·Endocrine, Metabolic & Immune Disorders - Drug Targets

Hypophysitis Induced by Sintilimab in the Treatment of Bladder Cancer: A Case Report

作者: Zhou, Yaru ; Yang, Shijie ; Li, Ran ; Zhu, Yiran ; Gao, Likuan ; Jiang, Baichuan

Background::

Immune checkpoint inhibitors (ICIs), as novel antitumor drugs, have been widely used in the clinic and have shown good antitumor effects. However, their wide-spread use has also led to the emergence of various immune-related adverse events (IrAEs). Hypophysitis is a rare but serious IrAE. Due to its complex and changeable clinical manifestations, hypophysitis may be easily overlooked, leading to delayed diagnosis and treatment

Case Presentation::

A 68-year-old male patient was diagnosed with bladder cancer (T2bNXM0) in October 2021. He received two cycles of immunotherapy with sintilimab and chemotherapy with gemcitabine and cisplatin (GC). One month after the second treatment, he gradually developed recurrent fever, anorexia, drowsiness, and delirium. Laboratory examination revealed hyponatremia, decreased adrenocorticotropic hormone, and hypocortisolemia. The pituitary MRI showed no abnormality. The patient was diagnosed with immunotherapy-induced hypophysitis (IH) caused by sintilimab, leading to downstream endocrine disorders. With hormone replacement therapy, he was in a good mood, had a good appetite, and made an overall recovery.

Conclusion::

Immunotherapy-induced hypophysitis (IH) can result in a severe adrenal crisis, and prompt recognition and diagnosis are crucial. Clinicians must remain vigilant for the possibility of IH in patients who exhibit recurrent fever, anorexia, cognitive decline, and personality changes following ICI treatment. It is imperative to consider this diagnosis early to initiate appropriate management promptly.

1,627

项与信迪利单抗相关的新闻（医药）

2024-04-25

·药闻康策

中国医保肿瘤用药发展史

☝ 点击上方一键预约 ☝ 最新最热的医药健康新闻政策开栏语肿瘤已成为危害人类健康的“头号杀手”。近年来我国恶性肿瘤发病、死亡人数持续上升，治疗费用持续攀升，目前已成为占用医保基金最大的领域之一。中国癌症中心的数据表明，2022年我国新发癌症患者482.47万例，死亡257.42万例，均居全球第一。毫无疑问肿瘤已经成为威胁全民健康、增加患者医药负担的重要原因。肿瘤治疗具有周期长、费用高、预后不确定的特点。近年来一大批新药陆续上市，给患者救治带来了希望。但新药价格往往十分普遍昂贵，“望药兴叹”成为广大患者不可承受之重。疾病无情医保有情。国家医保局立足维护人民健康的职责定位，及时将符合条件的肿瘤治疗药物纳入医保，特别是通过准入谈判，发挥战略购买优势，引导肿瘤治疗领域新药价格回归合理，使原来价格昂贵、普通百姓可望不可及的肿瘤药能够惠及广大患者，推动我国肿瘤治疗临床用药水平迅速比肩国际主流。现行版医保目录共计有西药和中成药3088种，其中肿瘤治疗相关用药241种。自2018年国家医保局成立以来，医保目录累计新增744种药品，其中肿瘤用药达到100种，在所有治疗领域中高居首位。2018年至2023年底，协议期内谈判药品累计受益近3000万人次，医保基金支出超千亿元，实际报销比例近70%。在医保政策的协同支持下，我国肿瘤防治成效初显。目前我国恶性肿瘤的5年相对生存率达40.5%，较10年前提升了10个百分点。在医保部门不懈努力下，广大参保患者对新药迅速实现了付得起、用得上、有保障的目标。为做好医保政策和肿瘤防治知识宣传，中国医疗保险的“小保”和知名药学科普公众号“药葫芦娃”携手出品《肿瘤防治，医保护航》系列科普文章并开设专栏，将在4月15-21日的第30个全国肿瘤防治宣传周期间每日一篇，对医保药品政策和抗肿瘤药物知识进行科普解读，带您揭开医保目录内抗肿瘤药物的神秘面纱！人类肿瘤药物治疗史上的三次革命：从化疗药物到靶向药物、免疫治疗药物——中国医保肿瘤用药发展史肿瘤已成为危害人类健康的“头号杀手”，但是人类从来没有因为恐惧而停止对癌症病因、疾病机制和治疗方法的探索。人类一直在与全民公敌——癌症不懈奋战。随着时代的进步，抗肿瘤药物方面的研发也在不断创新。肿瘤药物治疗也经历了三次革命，越来越多的肿瘤药被及时纳入医保支付范围，使肿瘤患者的生存状况得到了极大的改善。第一次革命：化疗药物20世纪40年代，氮芥作为最早使用于临床的抗肿瘤药，用于治疗淋巴瘤和何杰金氏病。此后，随着抗癌药物的研究开发，化疗药物得到了快速的发展，一些肿瘤的联合化疗方案也陆续趋于成熟。阿霉素、顺铂、紫杉醇、吉西他滨……常用的化疗药物延长了不少患者的生命。时至今日，化疗仍然是多数瘤种的标准治疗方案。但化疗药物也存在较强的副作用，无法做到精准杀死癌细胞，往往是杀敌一千，自损八百。因此科学家一直在努力寻找可精准命中癌细胞，减少对正常组织或细胞损伤的治疗手段。第二次革命：靶向药物随着DNA双螺旋结构的破解，信号传导通路的相继发现，找到了多个与肿瘤发生、发展有关的位点，最终靶向药物应运而生，如针对表皮生长因子受体（EGFR）基因突变的吉非替尼、间变性淋巴瘤激酶（ALK）阳性的克唑替尼、费城染色体阳性的伊马替尼等。靶向药物可以精准地瞄准靶点发挥作用，不影响肿瘤周围的正常组织细胞，为广大肿瘤患者带来福音。但若是靶点基因发生了突变，靶向药物就会失去目标，丧失疗效。第三次革命：免疫治疗药物肿瘤的发生与人体免疫机制息息相关。全世界首个PD-1药物于2014年在日本首先上市，2018年下半年我国也陆续批准了多个PD-1/PD-L1药物，特别是2019年以后信迪利单抗、特瑞普利单抗、卡瑞利珠单抗、替雷利珠单抗等被纳入国家医保药品目录，以覆盖瘤种全、适用人群广、抗瘤活性久、不良反应轻的独特优势，在临床实践中广泛应用，对中国肿瘤的临床治疗产生了巨大影响。广大参保患者临床用药需求是医疗保障关注的重中之重。如前所述，现行版国家医保目录内的肿瘤治疗药物已达241种，不仅是数量增加，水平也不断提升，从最初的化疗药物，逐渐增加了靶向药物和免疫治疗类抗肿瘤药，为广大肿瘤患者提供了全面、可及的保障。特别是国家医保局成立以来，主动适应临床医药科技进步和参保人员用药需求的变化，建立常态化、动态化的医保药品目录调整机制，实现了目录内肿瘤靶向药物（免疫药物）从无到有，从少到多，从有到优的转变。一大批原来市场价格昂贵的靶向药物（免疫药物）如奥希替尼、信迪利单抗、尼拉帕利等通过谈判以适宜价格纳入医保支付范围。在大幅减轻患者经济负担的同时，显著提升了我国肿瘤临床用药水平，在较短时间内实现了从化疗为主到靶向药、免疫治疗药物广泛应用的跨越，广大肿瘤患者的用药保障水平得到了极大提升。（来源:中国医疗保险）药闻康策新媒体矩阵微信公众号点击下方一键关注【免责声明】1.“药闻康策”部分文章信息来源于网络转载是出于传递更多信息之目的，并不意味着赞同其观点或证实其内容的真实性。如对内容有疑议，请及时与我司联系。2.“药闻康策”致力于提供合理、准确、完整的资讯信息，但不保证信息的合理性、准确性和完整性，且不对因信息的不合理、不准确或遗漏导致的任何损失或损害承担责任。3.“药闻康策”所有信息仅供参考，不做任何商业交易或医疗服务的根据，如自行使用“药闻康策”内容发生偏差，我司不承担任何责任，包括但不限于法律责任，赔偿责任。欢迎转发分享、点赞、点在看

免疫疗法放射疗法

2024-04-25

·BiG生物创新社

ASCO 2024丨这些中国临床专家，将分享最新重磅研究

2024年美国临床肿瘤学会(ASCO)年会将于5月31日到6月4日在芝加哥举办，是世界上规模最大、学术水平最高、最具权威性的临床肿瘤学会议，会议汇集了全球肿瘤学医生和专业人士、患者倡导者、工业界代表和主要媒体，共同探讨当前国际最前沿的研究发现和临床试验成果。ASCO成立于1964年,是世界上最大、最具影响力的肿瘤专业学术组织,致力于癌症的预防、治疗及改善对患者的护理。ASCO在全球150多个国家和地区拥有超过45,000名成员。4月24日晚，ASCO官网公布了本次大会的研究标题，几十余名中国专家将在世界舞台上展示其研究成果，报告涵盖了多个瘤种的最新治疗策略和技术，展示了中国在全球癌症研究中的重要地位和贡献。世易编辑团队精心整理了中国专家们的研究报告，供您参考。全体大会报告Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study. Abstract: LBA4 · Suresh S. Ramalingam教授，美国埃默里大学Winship癌症研究所· 陆舜教授，上海交通大学附属胸科医院口头报告Lung Cancer—Non-Small Cell MetastaticSacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study. Abstract: 8502 · 方文峰教授，中山大学肿瘤防治中心 Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial. Abstract: 8508 · 张力教授，中山大学肿瘤防治中心 Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Adjuvant icotinib of 12 months or 6 months versus observation following adjuvant chemotherapy for resected EGFR-mutated stage II–IIIA non-small-cell lung cancer (ICTAN, GASTO1002): A randomized phase 3 trial. Abstract: 8004 ·王思愚教授，中山大学肿瘤防治中心 A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091). Abstract: 8008 · 刘慧教授，中山大学肿瘤防治中心 Taiwan national lung cancer early detection program for heavy smokers and non-smokers with family history of lung cancer. Abstract: 8009 · Pan-Chyr Yang, MD, PhD，台湾大学医学院 Gastrointestinal Cancer—Colorectal and Anal Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labeled, phase Ib study. Abstract: 3505 · 徐瑞华教授，中山大学肿瘤防治中心 Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Phase I study of CN201, a novel CD3xCD19 IgG4 bispecific antibody, in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Abstract: 6505 · 王迎教授，中国医学科学院血液病医院 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia CLAMP: A phase II prospective study of camrelizumab combined with pegaspargase, etoposide, and high-dose methotrexate in patients with natural killer (NK)/T-cell lymphoma. Abstract: 7002 · 刘涛教授，华中科技大学同济医学院附属协和医院 Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study. Abstract: LBA7003 · 赵维莅教授，上海交通大学医学院附属瑞金医院 Hematologic Malignancies—Plasma Cell DyscrasiaPhase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ). Abstract: 7500 ·Thierry Facon, MD，University of Lille, CHU Lille·刘卓刚教授，中国医科大学附属盛京医院Central Nervous System Tumors Efficacy and safety of the vebreltinib in patients with previously treated, secondary glioblastoma/IDH mutant glioblastoma with PTPRZ1-METFUsion GENe (FUGEN): A randomised, multicentre, open-label, phase II/III trial. Abstract: 2003 · Zhaoshi Bao, MD, PhD，首都医科大学附属北京天坛医院 High-dose almonertinib in treatment-naïve EGFR-mutated NSCLC with CNS metastases: Efficacy and biomarker analysis. Abstract: 2007 · 范云教授，浙江省肿瘤医院 SarcomaUpdated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma. Abstract: 11502 · 邱海波教授，中山大学肿瘤防治中心 Sintilimab, doxorubicin and ifosfamide (AI) as first-line treatment in patients with advanced undifferentiated pleomorphic sarcoma (UPS), synovial sarcoma (SS), myxoid liposarcoma (MLPS) and de-differentiated liposarcoma (DDLPS): A single-arm phase 2 trial. Abstract: 11505 · 罗志国教授，复旦大学附属肿瘤医院 ARTEMIS-002: Phase 2 study of HS-20093 in patients with relapsed or refractory osteosarcoma. Abstract: 11507 · 谢璐教授，北京大学人民医院 Head and Neck Cancer Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial. Abstract: LBA6000 · 刘需教授，中山大学肿瘤防治中心 Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial. Abstract: 6001 · 陈秋燕教授，中山大学肿瘤防治中心 Endostar combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A phase III, prospective, randomised-controlled, multicenter clinical trial. Abstract: 6002 · 康敏教授，广西医科大学第一附属医院 Developmental Therapeutics—ImmunotherapyClaudin18.2-targeted chimeric antigen receptor T cell-therapy for patients with gastrointestinal cancers: Final results of CT041-CG4006 phase 1 trial. Abstract: 2501 · 齐长松教授，北京大学肿瘤医院 A potential best-in-class BCMA-CD19 bispecific CART with advanced safety by self-inhibiting IFNG signaling during CRS. Abstract: 2502 · Lei Xue Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: Results from phase 1/2 studies. Abstract: 2504 · Chang Liu, MD，北京大学肿瘤医院Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Phase I/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors.Abstract: 3002· Wungki Park, MD, MS，美国纪念斯隆凯瑟琳癌症中心· 张剑教授，复旦大学附属肿瘤医院Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors. Abstract: 3008 · 赵军教授，北京大学肿瘤医院快速口头摘要报告 Lung Cancer—Non-Small Cell Metastatic A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon 20 insertion mutations: Primary analysis of WU-KONG1 study. Abstract: 8513 · James Chih-Hsin Yang 教授，台大肿瘤中心 Efficacy and safety of taletrectinib in patients with advanced or metastatic ROS1+ non–small cell lung cancer: The phase 2 TRUST-I study. Abstract: 8520 · 李玮教授，同济大学附属上海市肺科医院 Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Overall survival of adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line treatment for extensive-stage small cell lung cancer. Abstract: 8014 · 陈大卫教授，山东省肿瘤医院 Breast Cancer—Metastatic ACE-Breast-02: A pivotal phase II/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC). Abstract: 1020 · 胡夕春教授，复旦大学附属肿瘤医院 Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary Efficacy and safety of cadonilimab in combination with pulocimab and paclitaxel as second-line therapy in patients with advanced gastric or gastroesophageal junction (G/GEJ) cancer who failed immunochemotherapy: A multicenter, double-blind, randomized trial. Abstract: 4012 · 张小田教授，北京大学肿瘤医院 Phase I study of C-CAR031, a GPC3-specific TGFβRIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC). Abstract: 4019 · 章琦教授，浙江大学医学院附属第一医院肝胆胰外科 Gastrointestinal Cancer—Colorectal and Anal Total neoadjuvant treatment with long-course radiotherapy versus concurrent chemoradiotherapy in local advanced rectal cancer with high risk factors (TNTCRT): A multicenter, randomized, open-label, phase 3 trial. Abstract: LBA3511 · Xin Wang, MD，四川大学华西医院 Phase I trial of hypoxia-responsive CEA CAR-T cell therapy in patients with heavily pretreated solid tumor via intraperitoneal or intravenous transfusion. Abstract: 3514 · Hangyu Zhang，浙江大学医学院第一附属医院 Three-year disease-free survival after transanal vs. laparoscopic total mesorectal excision for rectal cancer (TaLaR): A randomized clinical trial. Abstract: 3516 · 康亮教授，中山大学附属第六医院 Genitourinary Cancer—Kidney and Bladder Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: A single-arm, open-label, phase 2 trial. Abstract: 4511 · Zhigong Wei，四川大学华西医院 Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Latest results of a phase 2 study of IMM01 combined with azacitidine (AZA) as the first-line treatment in adults with higher risk myelodysplastic syndromes (MDS). Abstract: 6510 · Wei Yang，中国医科大学附属盛京医院 Safety and efficacy of CD7-CAR-T cell in patients with relapsed/refractory T-lymphoblastic leukemia/lymphoma: Phase I dose-escalation/dose-expansion study. Abstract: 6515 · Lijuan Hu, MD, 北京大学人民医院 Hematologic Malignancies—Plasma Cell Dyscrasia OriCAR-017, a novel GPRC5D-targeting CAR-T, in patients with relapsed/refractory multiple myeloma: Long term follow-up results of phase 1 study (POLARIS). Abstract: 7511 · Shan Fu，浙江大学医学院附属第一医院 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Timdarpacept (IMM01) in combination with tislelizumab in prior anti-PD-1 failed classical Hodgkin lymphoma: An open label, multicenter, phase II study (IMM01-04) evaluating safety as well as preliminary anti-tumor activity. Abstract: 7017 · Zhenjiu Wang, MD Gynecologic Cancer Efficacy and safety of sintilimab plus paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer: A phase II trial. Abstract: 5512 ·刘继红教授，中山大学肿瘤防治中心 Nimotuzumab plus concurrent chemoradiotherapy for locally advanced cervical squamous cell carcinoma: The randomized, phase 3 CC3 study. Abstract: 5514 ·王俊杰教授，北京大学第三人民医院 A phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer (SCORES). Abstract: LBA5516 · 袁光文教授，中国医学科学院肿瘤医院 Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): A final overall survival analysis of a multicenter, open-label, randomized, phase 3 trial. Abstract: 5520 · 臧荣余教授，复旦大学附属中山医院 Head and Neck Cancer Preliminary results of phase I/II study to evaluate safety and efficacy of combination pucotenlimab with epidermal growth factor receptor-ADC (EGFR-ADC) MRG003 in patients with EGFR positive solid tumors. Abstract: 6013 · 阮丹云教授，中山大学肿瘤防治中心 Covalent FAPI PET enables accurate management of medullary thyroid carcinoma: a prospective single-arm comparative clinical trial. Abstract: LBA6018 · Ziren Kong, MD, 中国医学科学院北京协和医学院 Sarcoma A phase II study of anlotinib and an anti-PDL1 antibody in patients with alveolar soft part sarcoma: Results of expansion cohorts. Abstract: 11515 · 刘佳勇教授，北京大学肿瘤医院 Phase 1 study of NB003, a broad-spectrum KIT/PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST). Abstract: 11518 · 李健教授，北京大学肿瘤医院 Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Results of a phase 1/2 study of MHB088C: A novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors. Abstract: 3012 · 沈琳教授，北京大学肿瘤医院 9MW2821, a nectin-4 antibody-drug conjugate (ADC), in patients with advanced solid tumor: Results from a phase 1/2a study. Abstract: 3013 · 张剑教授，复旦大学附属肿瘤医院 Developmental Therapeutics—Immunotherapy Phase I study of GUCY2C CAR-T therapy IM96 in patients with metastatic colorectal cancer. Abstract: 2518 · 齐长松教授，北京大学肿瘤医院 Safety and preliminary efficacy results of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: A phase 1 dose escalation and expansion study. Abstract: 2519 · 郑莉教授，四川大学华西医院 Symptom Science and Palliative Care Effect of nurse-led multi-disciplinary treatment on patients with head and neck tumors: A randomized controlled trial. Abstract: 12013 · Jingjing Wang, MD，四川大学华西医院肿瘤中心临床科学研讨会A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors: Cervical cancer cohort. Abstract: 5509 · Hui Xie，德琪医药有限公司临床研发部 KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. Abstract: LBA8509 · Tony S. K. Mok 教授，香港大学 Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study. Abstract: 104 · 樊英教授，中国医学科学院肿瘤医院 Efficacy of disitamab vedotin (RC48) plus tislelizumab and S-1 as first-line therapy for HER2-overexpressing advanced stomach or gastroesophageal junction adenocarcinoma: A multicenter, single-arm, phase II trial (RCTS). Abstract: 4009 · 刘联教授，山东大学齐鲁医院 A novel and uniquely designed bispecific antibody (LBL-024) against PD-L1 and 4-1BB in patients with advanced malignant tumors and neuroendocrine carcinoma: A report of safety and robust efficacy of LBL-024 monotherapy in phase I/II, first-in-human, open-label, multicenter, dose escalation/expansion study. Abstract: 4010 · 张盼盼医生，北京大学肿瘤医院 Safety and efficacy of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with advanced pancreatic ductal adenocarcinoma: Preliminary results from a phase 1 study. Abstract: 4011 · 郝继辉教授，天津医科大学肿瘤医院 Neoadjuvant sintilimab and platinum-doublet chemotherapy followed by transoral robotic surgery for HPV-associated resectable oropharyngeal cancer: Single-arm, phase II trial. Abstract: 6011 · 宋明教授，中山大学肿瘤防治中心 BiG 十周年预告本次BiG十周年庆典，将首次分为国内和国际篇章，以原创科学和临床需求为出发点，讨论创新技术平台和创新疗法（PROTACT/分子胶、双抗/ADC、siRNA/ASO、CGT、AI制药）的重大进展和发展前景，十年一药曙光现，大浪淘沙始见金！▼报名参会会议门票：审核制(免费)；含主论坛+分论坛，不含餐；优先biotech/Pharma、临床、院校科学家共建Biomedical创新生态圈！如何加入BiG会员？

ASCO会议临床结果

2024-04-25

·信达生物

信达生物将在美国临床肿瘤学会（ASCO）2024年大会公布多项临床数据

2024年4月25日，美国旧金山和中国苏州——信达生物制药集团（香港联交所股票代码：01801），一家致力于研发、生产和销售肿瘤、自身免疫、代谢及心血管、眼科等重大疾病领域创新药物的生物制药公司，今日宣布，将在 2024 年美国临床肿瘤学会（ASCO）年会上公布约20项最新临床研究数据，包括公司旗下一系列单抗、双抗及抗体偶联药物（ADC）在研管线，及达伯舒®（信迪利单抗注射液）、耐立克®（奥雷巴替尼）、他雷替尼（ROS1抑制剂）等创新肿瘤药物。本届 ASCO 年会将于当地时间2024年5月31日-6月4日在美国芝加哥举办。信达生物制药集团高级副总裁周辉博士表示：“很高兴在本次ASCO大会上首次公布了信达生物多个下一代创新肿瘤双抗及ADC分子的临床数据，早期探索取得的成果令我们欣喜，也使我们对于进一步开发充满信心。作为少数拥有“IO+ADC”技术平台和充沛管线储备的生物制药企业，信达生物将在癌症治疗领域持续取得突破，致力于为医生和患者提供更创新、有效和安全的治疗手段及方案。”重要临床研究结果摘要信息如下：IBI363 (PD-1/IL-2 双特异性抗体融合蛋白)(共三项，滑动查看更多）摘要标题：全球首创（First-in-class） PD-1/IL-2双特异性抗体融合蛋白IBI363在晚期结直肠癌患者中的I期研究：安全性和有效性初步结果摘要编号：3593会议类型及展现形式：壁报分会场-消化道肿瘤-结直肠和肛门癌展示时间：2024年6月1日下午1:30-4:30 (美国中部时间)演讲者：浙江大学医学院附属第一医院陈怡文教授摘要标题：全球首创（First-in-class） PD-1/IL-2双特异性抗体融合蛋白IBI363治疗晚期黑色素瘤：I期研究的安全性和有效性初步结果摘要编号：9562 会议类型及展现形式：壁报分会场-黑色素瘤/皮肤癌展示时间：2024年6月1日下午1:30 -4:30 (美国中部时间)演讲者：福建省肿瘤医院陈誉教授摘要标题：PD-1/IL-2双特异性抗体融合蛋白IBI363治疗其他实体瘤患者：I期研究的安全性和有效性初步结果摘要编号：e14593 会议类型及展现形式：在线发表展示时间：2024年5月23日下午5:00 （*美国东部时间）演讲者：浙江大学医学院附属第一医院白雪莉教授IBI389 (抗CLDN18.2/CD3 双特异性抗体)(共两项，滑动查看更多）摘要标题：抗CLDN18.2/CD3双特异性抗体IBI389在实体瘤和胃或胃食管肿瘤患者中的安全性和初步疗效结果：I期剂量递增和扩展研究摘要编号：2519会议类型及展现形式：快速口头报告-开发性治疗药物-免疫疗法展示时间：2024年6月2日上午11:30-下午1:00 (美国中部时间)演讲者：四川大学华西医院郑莉教授摘要标题：抗CLDN18.2/CD3双特异性抗体IBI389在晚期胰腺导管腺癌患者中的安全性和疗效：I期研究的初步结果摘要编号：4011 会议类型及展现形式：口头报告（临床科学研讨会）-消化道肿瘤的新型抗体疗法展示时间：2024年6月2日下午4:30 -6:00 (美国中部时间)演讲者：天津市肿瘤医院郝继辉教授 IBI343 (抗CLDN18.2 ADC)摘要标题：IBI343（抗Claudin18.2 ADC）在晚期胰腺导管腺癌或胆道癌患者的安全性和疗效：I期研究的初步结果摘要编号：3037会议类型及展现形式：壁报分会场-开发治疗-分子靶向药物和肿瘤生物学展示时间：2024年6月1日上午9:00-12:00 (美国中部时间)演讲者：复旦大学附属肿瘤医院虞先濬教授IBI310 (抗CTLA-4抗体)摘要标题：IBI310（抗CTLA-4抗体）联合信迪利单抗（抗PD-1抗体）对微卫星高度不稳定性（MSI-H）/错配修复缺陷(dMMR)结直肠癌患者的新辅助治疗：一项随机、开放标签的 Ib 期研究结果摘要编号：3505会议类型及展现形式：口头报告-消化道肿瘤-结直肠和肛门癌展示时间：2024年6月2日上午8:00-11:00 (美国中部时间)演讲者：中山大学肿瘤防治中心徐瑞华教授他雷替尼（ROS1抑制剂）摘要标题：他雷替尼在晚期或转移性 ROS1阳性非小细胞肺癌患者的疗效和安全性：II期TRUST-I研究摘要编号：8520会议类型及展现形式：快速口头报告-肺癌-晚期非小细胞肺癌展示时间：2024年6月1日下午4:30-6:00 (美国中部时间)演讲者：同济大学附属上海市肺科医院李玮教授IBI110 (抗LAG-3抗体)摘要标题：IBI110（抗LAG-3抗体）联合信迪利单抗（抗PD-1抗体）治疗晚期肺泡软组织肉瘤患者的有效性和安全性：II期研究结果摘要编号：11559会议类型及展现形式：壁报分会场-肉瘤展示时间：2024年6月1日下午1:30-4:30 (美国中部时间)演讲者：北京大学肿瘤医院刘佳勇教授达伯舒®(信迪利单抗)1 (共九项，滑动查看更多）摘要标题：信迪利单抗联合紫杉醇和顺铂新辅助治疗局晚期宫颈癌的疗效和安全性：一项II期研究摘要编号：5512会议类型及展现形式：快速口头报告-妇科肿瘤展示时间：2024年6月1日上午8:00-9:30 (美国中部时间)演讲者：中山大学肿瘤防治中心刘继红教授摘要标题：新辅助信迪利单抗联合含铂双药化疗后进行经口机器人手术治疗 HPV 相关可切除口咽癌：单臂，II期临床研究摘要编号：6011 会议类型及展现形式：口头报告（临床科学研讨会）-精准切除：可手术切除的HPV阳性口咽癌的治疗决策展示时间：2024年6月3日下午3:00-4:00 (美国中部时间)演讲者：中山大学肿瘤防治中心宋明教授摘要标题：单臂2期研究：信迪利单抗联合阿霉素和异环磷酰胺 (AI) 作为晚期未分化多形性肉瘤 (UPS)、滑膜肉瘤 (SS)、粘液样脂肪肉瘤 (MLPS) 和去分化脂肪肉瘤 (DDLPS) 患者的一线治疗疗效和安全性摘要编号：11505 会议类型及展现形式：口头报告-肉瘤展示时间：2024年6月3日下午3:00-6:00 (美国中部时间)演讲者：复旦大学附属肿瘤医院罗志国教授摘要标题：BBCAPX-II研究生存结果更新：信迪利单抗联合贝伐珠单抗和CapeOx一线治疗RAS突变、MSS、不可切除的转移性结直肠癌摘要编号：3563 会议类型及展现形式：壁报分会场-消化道肿瘤-结直肠和肛门癌展示时间：2024年6月1日下午1:30-4:30 (美国中部时间)演讲者：浙江大学医学院附属第二医院袁瑛教授摘要标题：信迪利单抗联合白蛋白紫杉醇二线治疗局晚期或转移性胃/胃食管结合部腺癌（G/GEJA）的疗效及生物标志物分析更新结果摘要编号：4037 会议类型及展现形式：壁报分会场-消化道肿瘤-胃食管、胰腺及肝胆肿瘤展示时间：2024年6月1日下午1:30-4:30 (美国中部时间)演讲者：中国医学科学院肿瘤医院姜志超教授摘要标题：信迪利单抗联合阿昔替尼治疗晚期FH缺陷肾细胞癌：一项多中心、开放标签、单臂、II期研究（SAFH）摘要编号：4523 会议类型及展现形式：壁报分会场-泌尿生殖系统肿瘤-肾和膀胱肿瘤展示时间：2024年6月2日上午9:00-12:00 (美国中部时间)演讲者：四川大学华西医院曾浩教授摘要标题：信迪利单抗联合安罗替尼一线治疗晚期非透明细胞肾癌（nccRR）：一项探索性、前瞻性、多中心临床研究的初步结果摘要编号：4544 会议类型及展现形式：壁报分会场-泌尿生殖系统肿瘤-肾和膀胱肿瘤展示时间：2024年6月2日上午9:00-12:00（美国中部时间）演讲者：中山大学肿瘤防治中心董培教授摘要标题：信迪利单抗联合呋喹替尼治疗晚期pMMR状态子宫内膜癌：一项多中心、单臂II期临床研究摘要编号：5619 会议类型及展现形式：壁报分会场-妇科肿瘤展示时间：2024年6月3日上午9:00-12:00（美国中部时间）演讲者：复旦大学附属肿瘤医院吴小华教授摘要标题：信迪利单抗联合化疗新辅助(2个周期vs.3个周期)治疗可切非小细胞肺癌（neoSCORE）：一项随机、II期临床研究的最终生存及探索性生物标志物分析结果摘要编号：8048会议类型及展现形式：壁报分会场-肺部肿瘤-非小细胞/小细胞/其他胸腺肿瘤展示时间：2024年6月3日下午1:30-4:30(美国中部时间)演讲者：浙江大学医学院附属第二医院邱福铭教授耐立克®(奥雷巴替尼) 摘要标题：奥雷巴替尼（HQP1351）治疗酪氨酸激酶抑制剂（TKI）耐药的琥珀酸脱氢酶缺陷型（SDH-）胃肠道间质瘤（GIST）和副神经节瘤患者的最新疗效数据摘要编号：11502会议类型及展现形式：口头报告-肉瘤展示时间：2024年6月3日下午3:00-6:00 (美国中部时间)演讲者：中山大学肿瘤防治中心邱海波教授关于信达生物- 滑动查看更多介绍 -“始于信，达于行”，开发出老百姓用得起的高质量生物药，是信达生物的使命和目标。信达生物成立于2011年，致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域的创新药物，让我们的工作惠及更多的生命。公司已有10个产品获得批准上市，它们分别是信迪利单抗注射液（达伯舒®），贝伐珠单抗注射液（达攸同®），阿达木单抗注射液（苏立信®），利妥昔单抗注射液（达伯华®），佩米替尼片（达伯坦®），奥雷巴替尼片（耐立克®），雷莫西尤单抗注射液（希冉择®）2，塞普替尼胶囊（睿妥®）2，伊基奥仑赛注射液（福可苏®）和托莱西单抗注射液（信必乐®）。目前，同时还有3个品种在NMPA审评中，5个新药分子进入III期或关键性临床研究，另外还有18个新药品种已进入临床研究。公司已与礼来、罗氏、赛诺菲、Adimab、Incyte和MD Anderson 癌症中心等国际合作方达成30多项战略合作。信达生物在不断自研创新药物、谋求自身发展的同时，秉承经济建设以人民为中心的发展思想。多年来，始终心怀科学善念，坚守“以患者为中心”，心系患者并关注患者家庭，积极履行社会责任。公司陆续发起、参与了多项药品公益援助项目，让越来越多的患者能够得益于生命科学的进步，买得到、用得起高质量的生物药。至2023年底，信达生物患者援助项目已惠及17余万普通患者，药物捐赠总价值34亿元人民币。信达生物希望和大家一起努力，提高中国生物制药产业的发展水平，以满足百姓用药可及性和人民对生命健康美好愿望的追求。详情请访问公司网站：www.innoventbio.com或公司领英账号Innovent Biologics。声明：信达生物不推荐未获批的药物/适应症的使用。1.除摘要5619外，信迪利单抗部分均为基于研究者申请发起的临床研究（IIT）。2.雷莫西尤单抗注射液（希冉择®）和塞普替尼胶囊（睿妥®）由礼来公司研发。前瞻性声明本新闻稿所发布的信息中可能会包含某些前瞻性表述。这些表述本质上具有相当风险和不确定性。在使用“预期”、“相信”、“预测”、“期望”、“打算”及其他类似词语进行表述时，凡与本公司有关的，目的均是要指明其属前瞻性表述。本公司并无义务不断地更新这些预测性陈述。这些前瞻性表述乃基于本公司管理层在做出表述时对未来事务的现有看法、假设、期望、估计、预测和理解。这些表述并非对未来发展的保证，会受到风险、不确性及其他因素的影响，有些乃超出本公司的控制范围，难以预计。因此，受我们的业务、竞争环境、政治、经济、法律和社会情况的未来变化及发展的影响，实际结果可能会与前瞻性表述所含资料有较大差别。

临床1期ASCO会议抗体药物偶联物临床结果

100 项与信迪利单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L01XC	DB15765

研发状态

适应症	最高研发状态	国家/地区	公司
肝细胞癌	批准上市	中国更多	信达生物制药（苏州）有限公司更多
非小细胞肺癌	批准上市	中国澳门更多	信达生物制药（苏州）有限公司更多
食管鳞状细胞癌	批准上市	中国更多	Innovent Biologics, Inc. 更多
晚期子宫内膜癌	申请上市	中国更多	信达生物制药（苏州）有限公司更多
食管癌	临床3期	西班牙更多	信达生物制药（苏州）有限公司更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04127227 (SPIRIT, Pubmed)	临床2期	结外NK-T细胞淋巴瘤一线 PD-1	34	Sintilimab + P-GEMOX	積觸鹹夢憲憲膚蓋獵繭(繭顧鹹鹽製鏇壓壓構膚) = 齋獵齋範構獵觸遞獵鬱壓願蓋艱鑰廠壓積獵繭 (鏇憲觸醖製襯繭範艱範, 54 ~ 95) 更多	积极	2024-03-27
NCT03574402 (CTONG 1702, ESMO_ELCC2024) 人工标引	临床2期	非小细胞肺癌一线 TMB-High \| PD-L1 Expression	63	sintilimab (PD-L1high)	積齋膚範鑰鏇鬱鏇壓糧(選繭範襯鹹範鑰壓鑰簾) = 鏇積願築構簾壓積遞網觸淵窪齋艱膚選蓋構淵 (築鹹選蓋選鹽鹹膚繭衊 ) 达到更多	积极	2024-03-20
NCT03574402 (CTONG 1702, ESMO_ELCC2024) 人工标引	临床2期	非小细胞肺癌一线 TMB-High \| PD-L1 Expression	63	sintilimab (TMBhigh)	積齋膚範鑰鏇鬱鏇壓糧(選繭範襯鹹範鑰壓鑰簾) = 膚膚餘繭繭遞憲窪鏇顧觸淵窪齋艱膚選蓋構淵 (築鹹選蓋選鹽鹹膚繭衊 ) 达到更多	积极	2024-03-20
NCT03985046 (Pubmed)	临床2期	食管癌 PD-1 inhibitors	-	Sintilimab, Paclitaxel, and Carboplatin	餘鏇醖艱選窪遞簾艱簾(鹽齋築襯艱鹹構艱艱範) = 鬱製鹽獵鏇觸夢鹽簾窪鬱選簾簾餘製衊蓋構遞 (淵願鑰廠構範鬱顧醖簾, 72.7% ~ 90.7%)	积极	2024-03-01
NCT03985046 (Pubmed)	临床2期	食管癌 PD-1 inhibitors	-	Carboplatin and Paclitaxel	餘鏇醖艱選窪遞簾艱簾(鹽齋築襯艱鹹構艱艱範) = 衊範構選積衊壓鹽憲夢鬱選簾簾餘製衊蓋構遞 (淵願鑰廠構範鬱顧醖簾 )	积极	2024-03-01
NEWS 人工标引	N/A	肝癌	21	信迪利单抗	網齋製壓觸製範糧繭遞(膚襯繭選憲網餘積衊願) = 壓齋鹽築衊衊鬱窪繭網鹽積艱襯夢積獵範襯艱 (網餘鏇鹽願醖顧鏇齋築 ) 更多	积极	2024-01-19
ChiCTR1900027433 (ASH2023)	临床2期	原发性中枢神经系统淋巴瘤	28	Sintilimab	鏇顧壓憲製淵壓衊製衊(夢願選鬱襯憲窪選選艱) = 遞鏇積糧憲蓋鏇範選鏇遞繭鬱遞艱夢網構糧獵 (膚鑰鬱糧醖積獵鹹醖廠, 81 ~ 99.9)	-	2023-12-11
ASH2023	临床2期	高危骨髓增生异常综合征	53	Anti-PD-1 Antibody (Sintilimab) + Decitabine	壓壓顧襯範簾顧積廠窪(鹽範齋膚獵鏇範憲鹹鹽) = 顧選齋蓋壓範衊積顧鹽淵範鹹衊製醖壓壓繭糧 (窪繭窪淵願鹽繭鑰廠憲 ) 更多	积极	2023-12-11
NCT03820596 (Scent Study, ASH2023)	临床1/2期	结外NK-T细胞淋巴瘤	37	Sintilimab + Chidamide	選鏇築窪遞製壓衊網選(壓顧衊獵獵襯餘築壓壓) = 築構鹹廠廠鑰憲網艱壓製鬱鏇餘構鏇製淵鏇簾 (構憲選夢膚壓餘餘艱餘 ) 更多	积极	2023-12-09
ASH2023	N/A	结外NK-T细胞淋巴瘤	33	Sintilimab 200mg	鏇壓獵蓋願壓築醖鏇醖(願積憲觸遞繭膚網範醖) = 觸壓餘鹹範衊獵憲艱壓簾鬱獵顧夢餘夢齋遞繭 (廠鹽繭構鬱糧壓蓋繭鑰 ) 更多	积极	2023-12-09
NCT03745170 (ORIENT-16, NEWS) 人工标引	临床3期	胃食管交界处腺癌一线 PD-L1 Positive	-	信迪利单抗+奥沙利铂+卡培他滨	艱窪壓淵淵蓋鑰積構範(鹹積壓鏇獵壓衊鹹觸蓋) = 壓襯繭鹹鹹膚鏇遞糧淵廠窪艱範願範憲壓遞餘 (憲願築範顧範夢網醖鏇 )	积极	2023-12-06
NCT03745170 (ORIENT-16, NEWS) 人工标引	临床3期	胃食管交界处腺癌一线 PD-L1 Positive	-	placebo+奥沙利铂+卡培他滨	艱窪壓淵淵蓋鑰積構範(鹹積壓鏇獵壓衊鹹觸蓋) = 餘鑰範範觸壓繭淵積製廠窪艱範願範憲壓遞餘 (憲願築範顧範夢網醖鏇 )	积极	2023-12-06
NCT03745170 (ORIENT-16, Literature) 人工标引	临床3期	胃食管交界处癌一线	650	Sintilimab+capecitabine+oxaliplatin	膚願夢積積鑰願鏇艱鏇(艱窪齋簾夢觸鏇顧顧膚) = 憲範醖鏇淵選壓膚艱衊鹹膚壓艱憲窪窪鑰廠繭 (糧齋淵蓋製構憲餘憲壓 ) 达到更多	积极	2023-12-05
NCT03745170 (ORIENT-16, Literature) 人工标引	临床3期	胃食管交界处癌一线	650	Placebo+capecitabine+oxaliplatin	膚願夢積積鑰願鏇艱鏇(艱窪齋簾夢觸鏇顧顧膚) = 顧壓鑰獵製製範壓鑰繭鹹膚壓艱憲窪窪鑰廠繭 (糧齋淵蓋製構憲餘憲壓 ) 达到更多	积极	2023-12-05